Catalyst Dossier · compiled by CeliA 🧫

Basilea Pharmaceutica (BSLN.SW)

Biotechnology · market cap $726M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Isavuconazole	Phase 3	Acute Myeloid Leukemia
ceftobiprole medocaril	Phase 3	Skin Diseases, Infectious
Vancomycin	Phase 3	Skin Diseases, Infectious
derazantinib	Phase 2	Intrahepatic Cholangiocarcinoma
Daptomycin	Phase 3	Staphylococcus Aureus Bacteremia
Derazantinib low dose range	Phase 2	Solid Tumor
alitretinoin	Phase 3	Hand Dermatoses
vancomycin+aztreonam	Phase 3	Acute Bacterial Skin and Skin Structure Infections
Fosmanogepix	Phase 3	Candidemia
IV standard-of-care cephalosporin	Phase 3	Community-acquired Pneumonia (CAP)
linezolid plus ceftazidime	Phase 3	Pneumonia
APX001	Phase 2	Candidemia
BAL101553	Phase 2	Neoplasms
Derazantinib 300 mg once daily monotherapy	Phase 2	Urothelial Carcinoma
Lisavanbulin Phase 1 dose escalation portion	Phase 2	Neoplasms
Ceftriaxone with or without Linezolid	Phase 3	Pneumonia
Fosmanogepix IV infusion	Phase 3	Invasive Mold Infections

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BSLN.SW (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 17 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.